Tomaralimab
mAbexperimental
Clinical trial activity
5 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2012 (NCT01794663)
Timeline
Indications
Mechanism of action
- Toll-like receptor 2ANTAGONIST
Toll-like receptor 2 antagonist
- Toll-like receptor 2INHIBITOR
TLR2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298067 ↗
Also known as
- opn-305
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06934941 | Phase 1 | Nov 25, 2024 | Neuramedy, Seoul National University |
| NCT05790382 | Phase 1 | May 10, 2023 | Neuramedy, Quotient |
| NCT03337451 | Phase 1/Phase 2 (Phase 2) | Feb 27, 2018 | New York Presbyterian Hospital, Opsona Therapeutics Ltd., University of South Florida, University of Texas at Houston, Yeshiva University |
| NCT02363491 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2015 | Opsona Therapeutics Ltd., University of Texas at Houston |
| NCT01794663 | Phase 2 | Oct 1, 2012 | Opsona Therapeutics Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Opsona Therapeutics Ltd. | For profit | 3 | 3 | 1 | 2012 |
| Neuramedy | For profit | 2 | 2 | 1 | 2023 |
| University of Texas at Houston | Academic/Hospital | 2 | 0 | 1 | 2015 |
| New York Presbyterian Hospital | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Quotient | For profit | 1 | 0 | 1 | 2023 |
| Seoul National University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of South Florida | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Yeshiva University | Academic/Hospital | 1 | 0 | 1 | 2018 |
8 organizations
Page 1 / 1